Investment Thesis
Oramed's reported $64M net income is driven by one-time non-operating gains, masking a fundamentally unprofitable business burning $9.1M in operating cash flow annually on just $2M in revenue. The pharmaceutical company's core operations show severe dysfunction with negative operating margins and negligible gross margins, though a strong balance sheet with $45.9M cash provides near-term runway.
Strengths
- Strong balance sheet with minimal debt ($502.7K liabilities vs $199.7M equity)
- Adequate cash position of $45.9M to fund near-term operations
- Revenue growth of 49.3% YoY from commercialization beginning
- Excellent liquidity ratios (6.98x current ratio) providing financial flexibility
- Significant asset base of $230.9M indicating previous successful capital raises
Risks
- Core operations deeply unprofitable with -$15.1M operating loss on $2M revenue base
- Negative operating cash flow of -$9.1M annually indicating unsustainable burn
- Net income appears to be one-time non-recurring gain masking operational reality
- Extraordinarily low 0.7% gross margin suggests pricing or production inefficiencies
- Unclear path to profitability with pharmaceutical company requiring years of R&D and regulatory approval
- At current burn rate, $45.9M cash exhausted within 5 years if operations don't improve
Key Metrics to Watch
- Quarterly revenue growth and path to gross margin profitability
- Operating cash flow trend and operating expense reduction
- Nature and sustainability of non-operating income items creating net income
- R&D pipeline progress and regulatory milestones for pipeline drugs
Financial Metrics
Revenue
2.0M
Net Income
64.1M
EPS (Diluted)
$1.50
Free Cash Flow
-9.2M
Total Assets
230.9M
Cash
45.9M
Profitability Ratios
Gross Margin
0.7%
Operating Margin
-754.4%
Net Margin
3,202.5%
ROE
32.1%
ROA
27.7%
FCF Margin
-457.7%
Balance Sheet & Liquidity
Current Ratio
6.98x
Quick Ratio
6.98x
Debt/Equity
0.37x
Debt/Assets
0.2%
Interest Coverage
-5.83x
Long-term Debt
74.6M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-13T19:48:30.656641 |
Data as of: 2025-12-31 |
Powered by Claude AI